Healthcare tech company Privia Health Group (NASDAQ:PRVA) will be reporting earnings this Thursday morning. Here’s what investors should know.
Privia Health beat analysts’ revenue expectations last quarter, reporting revenues of $603.8 million, up 25.8% year on year. It was a mixed quarter for the company, with full-year revenue guidance meeting analysts’ expectations but a significant miss of analysts’ EPS estimates.
Is Privia Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Privia Health’s revenue to grow 14.6% year on year, slowing from the 23.4% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Privia Health has a history of exceeding Wall Street’s expectations.
Looking at Privia Health’s peers in the healthcare technology segment, only Omnicell has reported results so far. It exceeded analysts’ revenue estimates, delivering year-on-year sales growth of 7.4%. The stock was down 14.6% on the results.
Read our full analysis of Omnicell’s earnings results here.Investors in the healthcare technology segment have had steady hands going into earnings, with share prices up 1.4% on average over the last month. Privia Health is down 12.5% during the same time and is heading into earnings with an average analyst price target of $31.89 (compared to the current share price of $23.79).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.